Cirius Suspects Insulin Resistance Is Underlying Key To NASH
The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.
You may also be interested in...
Cirius’ Mixed Phase IIb Results In NASH Don’t Quell Its Enthusiasm For Phase III
Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on liver histology, while also trying to show long-term cardiovascular benefits.
Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits
Phase IIb interim look shows liver enzyme reductions, signs of glycemic control and no increase in peripheral edema from baseline. Cirius expects to have final data in the second half of 2019.
Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements
Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.